By inhibiting ILK, DZ-50 is then able to kill tumor cells via blocking AKT and FAK phosphorylation and subsequent cell survival, disrupting integrin adhesion (α5β1 and α2β1), and engaging ECM associated tumor suppressors [3,30]. The gene discussed is ILK; the disease is neoplasm.